StreetInsider.com News Articles

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 16:05:00 -0400

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.

The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 16:05:00 -0400

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tue, 01 Sep 2026 07:00:00 -0400

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.

The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics
Tango

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tue, 01 Sep 2026 07:00:00 -0400

About Tango Therapeutics
Tango

Tango Therapeutics Inc. (TNGX) PT Raised to $68 at H.C. Wainwright

Tue, 18 Aug 2026 06:40:28 -0400

(Updated - August 18, 2026 6:40 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $68.00 (from $66.00) while maintaining a Buy rating.

The analyst commented: "For 2Q26, Tango recorded net earnings of $0.37 per share vs. our previously estimated net earnings of $0.30 per share. R&D and SG&A expenses were $37.2M and $22.6M, respectively vs. our estimates of $34.9M and $16M. We now project a full-year 2026 net loss of $1.34 per share vs. our prior net loss estimate of $1.14 per share. Tango ended 2Q26 with ~$1B in cash, cash equivalents,

Tango Therapeutics Inc. (TNGX) PT Raised to $68 at H.C. Wainwright

Tue, 18 Aug 2026 06:40:28 -0400

(Updated - August 18, 2026 6:40 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $68.00 (from $66.00) while maintaining a Buy rating.

Tango Therapeutics Inc. (TNGX) Reiterated at Buy by Stifel: 3 Catalysts by YE26

Mon, 17 Aug 2026 07:49:58 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $40.00 price target on Tango Therapeutics Inc. (NASDAQ: TNGX).

The analyst commented, "Expectations for the vopimetostat+RAS(ON) inhibitor combination ESMO 2026 poster? Expect longer follow-up from the June disclosure, with some additional patients. Management cautioned against expecting too many newly enrolled patients to be reflected in ESMO efficacy data - time window is pretty narrow to enroll patients who would have the 14+ weeks of required follow-up to be efficacy evaluable by the ESMO data cut-off. Investors expect around a doubling of the efficacy evaluable vopi+darax patients in PDAC (DL1+DL2) in the ESMO

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Nextech Crossover I GP S.a r.l.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932148.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Nextech Crossover I GP S.a r.l.

Fri, 14 Aug 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260814/26932148.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26930817.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260814/26930817.html

Form SCHEDULE 13G Tango Therapeutics, Inc. Filed by: GOLDMAN SACHS GROUP INC

Fri, 14 Aug 2026 14:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26928837.html

Form SCHEDULE 13G Tango Therapeutics, Inc. Filed by: GOLDMAN SACHS GROUP INC

Fri, 14 Aug 2026 14:12:00 -0400

si-local-file:///var/storage/secattach/20260814/26928837.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26927053.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260814/26927053.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26925038.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Fri, 14 Aug 2026 08:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26925038.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26911208.html

Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Adage Capital Management, L.P.

Wed, 12 Aug 2026 12:02:00 -0400

si-local-file:///var/storage/secattach/20260812/26911208.html

Tango Therapeutics Inc. (TNGX) PT Raised to $35 at Guggenheim

Wed, 12 Aug 2026 06:57:05 -0400

(Updated - August 12, 2026 6:57 AM EDT)

Guggenheim analyst Charles Zhu raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $35.00 (from $32.00) while maintaining a Buy rating.

The analyst commented: "TNGX reported 2Q26 results and highlighted that they will finalize the design of a planned Phase 3 randomized controlled trial for vopimetostat (PRMT5i) + RAS inhibitors (RVMD) in 1L PDAC in 2H26. Our discussion with mgmt focused on upcoming data disclosure at ESMO 2026 and potential registrational design in 1L PDAC, as well as recent changes in leadership. Mgmt remains confident in upcoming discussions with the FDA and

Tango Therapeutics Inc. (TNGX) PT Raised to $35 at Guggenheim

Wed, 12 Aug 2026 06:57:05 -0400

(Updated - August 12, 2026 6:57 AM EDT)

Guggenheim analyst Charles Zhu raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $35.00 (from $32.00) while maintaining a Buy rating.

Form 8-K Tango Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260811/26907016.html

Form 8-K Tango Therapeutics, Inc. For: Aug 11

Tue, 11 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260811/26907016.html

Form 424B5 Tango Therapeutics, Inc.

Tue, 11 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26906985.html

Form 424B5 Tango Therapeutics, Inc.

Tue, 11 Aug 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26906985.html